Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dmp1 and tumor suppression.

K Inoue1, A Mallakin, D P Frazier

  • 1Department of Pathology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC 27157-0001, USA. kinoue@wfubmc.edu

Oncogene
|January 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-kappaB subunit p65.

Oncogene·2007
Same author

Expression of Dmp1 in specific differentiated, nonproliferating cells and its regulation by E2Fs.

Oncogene·2006
Same author

Nicotine applied by transdermal patch induced HSV-1 reactivation and ocular shedding in latently infected rabbits.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2003
Same author

Pathway of anthracene modification under simulated solar radiation.

Chemosphere·2000
Same author

Impacts of structural photomodification on the toxicity of environmental contaminants: anthracene photooxidation products.

Ecotoxicology and environmental safety·1999
Same author

The herpes simplex virus type 1 latency-associated transcript promoter is activated through Ras and Raf by nerve growth factor and sodium butyrate in PC12 cells.

Journal of virology·1996

Cyclin D binding myb-like protein 1 (Dmp1) acts as a tumor suppressor by regulating the Arf-p53 pathway. Loss of Dmp1 accelerates tumor formation, highlighting its critical role in cell cycle control and cancer prevention.

Area of Science:

  • Molecular Biology
  • Cell Cycle Regulation
  • Oncology

Background:

  • Dmp1 (cyclin D binding myb-like protein 1) is a transcription factor identified via its interaction with cyclin D2.
  • Initially thought to be involved in the cyclin D-Rb pathway, Dmp1's role extends to cell cycle arrest.
  • Dmp1 is a novel regulator of Arf, with its promoter activated by oncogenic Ras-Raf signaling.

Purpose of the Study:

  • To investigate the function of Dmp1 in cell cycle regulation and tumor suppression.
  • To determine the relationship between Dmp1, Arf, and p53.
  • To assess the role of Dmp1 in oncogenesis using mouse models.

Main Methods:

  • Yeast two-hybrid screening to identify Dmp1 binding partners.
  • Overexpression studies in primary cells to analyze cell cycle effects.

Related Experiment Videos

  • Analysis of tumor formation in Dmp1 heterozygous and knockout mice.
  • Examination of Arf and p53 status in Dmp1-deficient tumors.

    • Main Results:

    • Dmp1 overexpression induces cell cycle arrest dependent on Arf and p53.
    • Dmp1 expression is repressed by mitogenic stimuli and E2F, marking cells exiting the cell cycle.
    • Dmp1 haploinsufficiency accelerates spontaneous and oncogene-induced tumor formation.
    • Tumors in Dmp1-deficient mice often retain wild-type Arf and p53, confirming Dmp1's role as a physiological Arf-p53 pathway regulator.

    Conclusions:

    • Dmp1 is a critical tumor suppressor that functions through the Arf-p53 pathway.
    • Dmp1 acts as a novel regulator of Arf, linking Ras-Raf signaling to cell cycle exit.
    • The human DMP1 gene locus is implicated in myeloid leukemia and solid tumors, suggesting its relevance in human malignancy.